 |
|
|
|
|
|
|
|
 |
Results for 'Schering AG: PharmaVitae Profile' |
|
|
| Title |
 |
Publication Date |
|
Price |
|
Relevance |
 |
|
|
|
|
Schering AG: PharmaVitae Profile
PharmaVitae Profile
|
December 2006 |
£3000 |
100 % |
Schering-Plough: PharmaVitae Profile
PharmaVitae Profile
|
September 2006 |
£3000 |
98 % |
Bayer Schering Pharma: PharmaVitae Profile
PharmaVitae Profile
|
December 2006 |
£3000 |
97 % |
Schering AG IMS Company Profile
|
November 2006 |
£510 |
66 % |
Schering AG Deals
Partneringdesk briefing
|
July 2005 |
£215 |
35 % |
Schering-Plough Corporation Deals
Partneringdesk briefing
|
July 2005 |
£215 |
31.85 % |
Schering-Plough Corporation
PharmaVitae Profile
|
July 2008 |
£3010 |
23.45 % |
ScheringPlough Partnering Guide 2008
|
July 2021 |
£195 |
23.45 % |
Bayer Schering Pharma AG - SWOT Analysis
|
March 2008 |
£66 |
21.5 % |
Schering-Plough Corp: OTC Healthcare
|
January 2007 |
£195 |
21.5 % |
Schering AG - SWOT Analysis
|
October 2008 |
£66 |
20.5 % |
Big Pharma M&A Analysis to 2012 - Surveying the growth rate landscape
|
August 2008 |
£3800 |
20.3 % |
Innovative And Targeted Cancer Therapies
Key Technologies, New Applications And Leading Players
|
July 2007 |
£1545 |
19.25 % |
Bayer Schering Pharma Ag
PharmaVitae Profile
|
July 2008 |
£3010 |
18.55 % |
PharmaVitae 2005: Schering AG Global Analysis
|
May 2005 |
£2005 |
18.5 % |
Schering-Plough Corporation - SWOT Analysis
|
March 2008 |
£66 |
18 % |
Eye Care in United States
|
May 2006 |
£450 |
16.45 % |
NRT Smoking Cessation Aids in United States
|
May 2006 |
£450 |
15.75 % |
Vitamins And Dietary Supplements in United States
|
May 2006 |
£450 |
15.75 % |
Medicated Skin Care in United States
|
May 2006 |
£450 |
15.75 % |
Digestive Remedies in United States
|
May 2006 |
£450 |
15.75 % |
Cough, Cold And Allergy (Hay Fever) Remedies in United States
|
May 2006 |
£450 |
15.05 % |
Pipeline/Commercial Insight: Innovative Targeted Therapies
Smart Drugs' on Target for Increasing Growth
|
October 2005 |
£8695 |
12.95 % |
Hepatitis C - Small-Molecule Antivirals Pave The Way For Triple Therapy
Stakeholder Opinions
|
December 2007 |
£2005 |
12.6 % |
Bigpharma Dealmaking Handbook
Companies & Contacts
|
September 2001 |
£2195 |
12.25 % |
Brain Metastases
Turning Prolonged Survival on its Head?
|
December 2004 |
£2005 |
12 % |
Bigpharma Dealmaking and Agreements Handbook 2007
Companies, Contacts & Partnering Agreements
|
September 2007 |
£1195 |
11.2 % |
Pipeline Insight: Endometriosis
Growing the Patient Population is Key to Unlocking the Market's Commercial Potential
|
July 2004 |
£6000 |
10.85 % |
Stakeholder Opinion: Erectile Dysfunction
Identifying product differentiation and patient segmentation strategies
|
December 2006 |
£2005 |
10 % |
Commercial Insight: Top 20 Therapy Cancer Brands Key brands set to consolidate advantage as competition intensifies
Key Brands Set to Consolidate Advantage as Competition Intensifies
|
August 2008 |
£7600 |
9.8 % |
The Global Antivirals Market
R&D Pipelines, Market Analysis and Competitive Landscape
|
May 2007 |
£1630 |
9.1 % |
Indonesia Pharmaceuticals and Healthcare Report Q3 2006
|
April 2007 |
£395 |
9 % |
Pharmaceutical Project and Portfolio Management
Effective organization and decision-making for long-term growth
|
January 2005 |
£1495 |
8.75 % |
Animal Pharm's Top Tier Companies
2007 edition
|
January 2007 |
£895 |
8.5 % |
Analytical Tool: Competitive Outlook on HCV
|
July 2004 |
£1275 |
8.5 % |
Pricing and Reimbursement Risk and Opportunity in Pharmaceutical Deal Making
|
May 2007 |
£1695 |
8.4 % |
Top 7 Cancer Indications
Therapeutic & Competitive Insights
|
January 2007 |
£5910 |
8.4 % |
U.S. Market for Over-the-Counter Pediatric Medication and Healthcare Products
|
March 2006 |
£1955 |
8.05 % |
The Dermatology Market Outlook to 2013
Competitive Landscape, Pipeline Analysis and Growth Opportunities
|
October 2008 |
£2025 |
8.05 % |
U.S. Market for Over-the-Counter Cough, Cold, Allergy, and Sinus Medications, The
|
July 2005 |
£1955 |
8.05 % |
Germany Ophthalmic Devices Investment Opportunities
Analysis and Forecasts to 2012
|
July 2008 |
£975 |
8.05 % |
Tanabe Prospects to 2010
Pipeline, Products,Performance,Potential
|
September 2007 |
£595 |
8 % |
Partnering with Biopharma
The definitive guide to bigpharma partnering interests, contacts & agreements
|
July 2001 |
£1495 |
7.7 % |
Licensing Strategies - Examining Todays Pharmaceutical Licensing Trends
|
November 2007 |
£7600 |
7.7 % |
Commercial and Pipeline Insight: Hepatitis B
|
October 2007 |
£7600 |
7.7 % |
Cannabinoids
A Potential Blockbuster
|
February 2005 |
£1499 |
7.5 % |
Fastest Growing Biotechnology Companies, The
Growth Strategies, Comparative Analyses and Company Profiles
|
March 2008 |
£1995 |
7.35 % |
United States Drug Delivery Devices Medical Equipment Industry Report
Detailed Analysis of the Medical Equipment & Medical Devices Market Covering Infusion Systems, Inhalation Systems and Needle Free Injections Medical Equipment and Supplies
|
April 2008 |
£990 |
7 % |
Stakeholder Opinions: Small Cell Lung Cancer and Malignant Mesothelioma
Limited R&D activity provides opportunity for early-phase pipeline drugs
|
March 2007 |
£2005 |
7 % |
Rimonabant: The first of the Cannabinoid blockbusters
|
June 2007 |
£1499 |
7 % |
Spain Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1955 |
6.65 % |
Italy Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1955 |
6.65 % |
Brazil Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1955 |
6.3 % |
South Africa Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1955 |
6.3 % |
UK Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1955 |
6.3 % |
United States Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2012
|
September 2008 |
£1060 |
6.3 % |
World Biotech Market 2005, The
|
June 2005 |
£4999 |
6.3 % |
Pipeline Insight: Non-Small Cell Lung Cancer
Pipeline set to offer only modest improvements
|
April 2008 |
£6000 |
6.3 % |
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies
More drugs on the market, more targets in the pipeline
|
October 2006 |
£8000 |
6.3 % |
Japan Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1955 |
6.3 % |
Stakeholder Opinions: Melanoma
Lucrative commercial opportunities persist
|
December 2006 |
£2005 |
6.3 % |
China Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1955 |
5.95 % |
Stakeholder Opinions: Primary Brain Cancer
Temozolomide Turns Heads
|
July 2007 |
£2005 |
5.95 % |
Australia Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1955 |
5.95 % |
Netherlands Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1955 |
5.95 % |
Italy Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£990 |
5.6 % |
United States Ophthalmic Devices Medical Equipment Industry Report
Detailed Analysis of the Medical Equipment & Medical Devices Market Covering Cataract Surgery, Refractive Surgery and Vision Care Equipment, Devices and Supplies
|
April 2008 |
£990 |
5.6 % |
Pipeline/Commercial Insight: Supportive Care in Oncology
Significant growth opportunities exist in new supportive care indications
|
June 2007 |
£7600 |
5.6 % |
CNS Drug Discoveries
What the Future Holds
|
November 2006 |
£1995 |
5.6 % |
UK Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£990 |
5.25 % |
South Africa Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£990 |
5.25 % |
Brazil Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£990 |
5.25 % |
Japan Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£990 |
5.25 % |
World Gastrointestinal Disorders Market 2008-2023
|
October 2008 |
£1499 |
5.25 % |
Australia Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£990 |
4.9 % |
Netherlands Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£990 |
4.9 % |
Forecast Insight: Multiple Sclerosis
Tysabri to prevail despite safety setbacks
|
August 2008 |
£7600 |
4.9 % |
Commercial and Pipeline Insight: HRT for Menopausal Symptoms
A new class restores an old market
|
April 2008 |
£8000 |
4.55 % |
Pipeline Insight: Anxiety Disorders
A decade of declining revenues
|
March 2006 |
£6495 |
4.2 % |
Maximizing Product Returns Through Reformulation
Old Molecules, New Opportunities
|
August 2004 |
£8000 |
3.85 % |
Orphan Drugs to 2008
Understanding regulation & market opportunity in Europe
|
January 2005 |
£800 |
3.85 % |
Epigenomics
Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics
|
March 2007 |
£3160 |
3.5 % |
Therapeutic Monoclonal Antibodies Report 2008-2023
|
July 2008 |
£1499 |
3.5 % |
The Executive Guide to Molecular Imaging
|
July 2007 |
£595 |
3.5 % |
Dr. Reddy's Market Outlook, Forecasts and Analysis to 2012
|
April 2007 |
£1499 |
3.15 % |
Dr. Reddy's Market Outlook, Forecasts and Analysis to 2012
|
April 2007 |
£1499 |
3.15 % |
Dr. Reddy's Market Outlook, Forecasts and Analysis to 2012
|
April 2007 |
£1499 |
3.15 % |
Dr. Reddy's Market Outlook, Forecasts and Analysis to 2012
|
April 2007 |
£1499 |
3.15 % |
Commercial Insight: Antidyslipidemics
Branded statins beware, generics are amongst you
|
July 2006 |
£8440 |
2.8 % |
PAREXEL's Bio/Pharma R&D Statistical Sourcebook 2008/2009
|
June 2008 |
£275 |
1.75 % |
Parexel's Pharmaceutical R&D Statistical Sourcebook 2007/2008
|
May 2007 |
£275 |
1.75 % |
|
|
|
|
